BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing
Rule 5635(c)(4)

SAN RAFAEL, Calif., Jan. 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical
Inc. (Nasdaq:BMRN) today announced that on January 15, 2013, the compensation
committee of BioMarin's board of directors approved the grant to 47 employees
of stock options to purchase 65,400 shares of common stock in the aggregate
and the grant to 46 of the 47 employees of 17,180 restricted stock units in
the aggregate. In addition, the compensation committee approved the grant of a
stock option to purchase 15,000 shares of common stock and 4,000 restricted
stock units to Shripad Bhagwat, a newly hired Vice President, Research. The
stock options were granted pursuant to the BioMarin Pharmaceutical Inc. 2012
Inducement Plan, approved by the compensation committee of BioMarin's board of
directors on May 8, 2012, and as inducements material to the new employees
entering into employment with BioMarin in accordance with NASDAQ Listing Rule
5635(c)(4).

BioMarin granted to Mr. Bhagwat and each of the 47 employees an option to
purchase shares of BioMarin's common stock with an exercise price equal to
$53.76, the closing price per share of BioMarin's common stock as reported by
NASDAQ on January 15, 2013, the date of grant. Each of the options is an
incentive stock option and will vest 6/48ths on the six month anniversary of
the grant date and 1/48th per month thereafter for the 42 immediately
following months, assuming in each case the employee remains continuously
employed by BioMarin. In addition, the restricted stock units granted to Mr.
Bhagwat and 46 of the 47 employees will vest in equal installments annually
over four years, assuming the employee remains continuously employed by
BioMarin. BioMarin is providing this information in accordance with NASDAQ
Listing Rule 5635(c)(4).

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
four approved products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme® (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis
I (MPS I), a product which BioMarin developed through a 50/50 joint venture
with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for
phenylketonuria (PKU), developed in partnership with Merck Serono, a division
of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine), which has
been approved by the European Commission for the treatment of Lambert Eaton
Myasthenic Syndrome (LEMS). Product candidates include BMN-110
(N-acetylgalactosamine 6-sulfatase), formally referred to as GALNS, which
successfully completed Phase III clinical development for the treatment of MPS
IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is
currently in Phase II clinical development for the treatment of PKU, BMN-701,
a novel fusion protein of insulin-like growth factor 2 and acid alpha
glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development
for the treatment of Pompe disease, BMN-673, a poly ADP-ribose polymerase
(PARP) inhibitor, which is currently in Phase I/II clinical development for
the treatment of genetically-defined cancers, and BMN-111, a modified
C-natriuretic peptide, which is currently in Phase I clinical development for
the treatment of achondroplasia. For additional information, please visit
www.BMRN.com. Information on BioMarin's website is not incorporated by
reference into this press release.

The BioMarin Pharmaceutical Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=11419

Forward Looking Statements

This press release contains certain forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995 regarding,
among other things, statements relating to plans, objectives and future
events. BioMarin intends such forward-looking statements to be covered by the
safe harbor provisions for forward-looking statements contained in Section 21E
of the Securities Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are based on
the current expectations of the management of BioMarin as of the date of this
press release and are subject to risks, uncertainties, changes in
circumstances, assumptions and other factors that may cause the actual results
to be materially different from those indicated by such forward-looking
statements. Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements include,
among other, market risks. These and other risks are described in greater
detail in BioMarin's filings with the Securities and Exchange Commission
(SEC), including its Annual Report on Form 10-K for the year ended December
31, 2011. Given these uncertainties, you should not place undue reliance on
these forward-looking statements. BioMarin assumes no obligation to update its
forward-looking statements, except as required by law.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of
BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

CONTACT: Investors:
         Eugenia Shen
         BioMarin Pharmaceutical Inc.
         (415) 506-6570
        
         Media:
         Debra Charlesworth
         BioMarin Pharmaceutical Inc.
         (415) 455-7451

BioMarin Pharmaceutical Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.